FIELD: pharmacology.
SUBSTANCE: invention relates to pharmacology and concerns the use of meso- and racemic forms of 2,6-di(1,7,7-trimethylbicyclo[2.2.1]heptane-exo-2-yl)-4-methylphenol as drugs for the treatment of cardiovascular diseases, correction of cerebral circulation disorders, treatment of consequences of cerebrovascular diseases. The meso-form is 2-{(1S, 2R, 4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl}-6-{(1R, 2S, 4S)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl}-4-methylphenol, the racemic form is 2,6-di{(1S,2R,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl}-4-methylphenol and 2,6-di{(1R,2S,4S)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl}-4-methylphenol.
EFFECT: technical result is expanding the arsenal of drugs for the treatment of cardiovascular diseases, correction of cerebral circulation disorders, treatment of consequences of cerebrovascular diseases, as well as enhancing pharmacological activity due to the stereospecific effect of isomers and due to the presence of a complex of pharmacological properties (antiradical, hemorheological, antiplatelet, antithrombogenic and neuroprotective activity, increase in cerebral blood flow), which also provides an increase in the effectiveness of treatment of the specified diseases.
2 cl, 7 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
AGENT RELIEVING POSTINFARCTION MYOCARDIAL REMODELING | 2020 |
|
RU2740895C1 |
MEDICATION FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2014 |
|
RU2555335C9 |
MEANS FOR CEREBRAL BLOOD FLOW INCREASE | 2016 |
|
RU2655810C2 |
AGENT POSSESSING NEUROPROTECTIVE ACTIVITY | 2018 |
|
RU2701739C1 |
AGENT IMPROVING RHEOLOGICAL PROPERTIES OF BLOOD | 2013 |
|
RU2546297C1 |
MEDICATION INCREASING BRAIN BLOOD FLOW | 2007 |
|
RU2351321C1 |
NEUROPROTECTOR | 2009 |
|
RU2406488C1 |
AGENTS WITH HEMORHEOLOGICAL, ANTIAGGREGANT AND ANTITROMBOGENIC ACTIVITY | 2007 |
|
RU2347561C2 |
2,6-DIISOBORNYLPHENOLS | 2011 |
|
RU2502719C2 |
ANTI-ISCHEMIC DRUG | 2012 |
|
RU2499593C1 |
Authors
Dates
2021-10-22—Published
2019-10-30—Filed